StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Jefferies Financial Group restated a “hold” rating and set a $0.50 price objective (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Finally, EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.32 on Tuesday. Marinus Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $11.26. The stock’s 50 day simple moving average is $1.04 and its two-hundred day simple moving average is $1.25. The company has a market cap of $17.93 million, a PE ratio of -0.13 and a beta of 1.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of MRNS. Vanguard Group Inc. raised its position in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Marinus Pharmaceuticals during the 1st quarter valued at $384,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $34,000. Values First Advisors Inc. raised its position in Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 52,257 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. raised its position in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares in the last quarter. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.